Stereotactic Body Radiotherapy for Centrally Located Inoperable Early-Stage NSCLC: EORTC 22113–08113 LungTech Phase II Trial Results
Journal of Thoracic Oncology · 2024-09 · 19 (9) · 1297-1309
DOI: 10.1016/j.jtho.2024.05.366 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Journal of Thoracic Oncology, 2024-09. Verfasst von Antonin Levy und 29 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Gustave Roussy, Université Paris Saclay, Villejuif, France. Hauptthemen laut MEDLINE: Radiosurgery, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: Cancer Research UK, Roche, Deutsche Krebshilfe.
Abstract (Originalsprache)
INTRODUCTION: The international phase II single-arm LungTech trial 22113-08113 of the European Organization for Research and Treatment of Cancer assessed the safety and efficacy of stereotactic body radiotherapy (SBRT) in patients with centrally located early-stage NSCLC. METHODS: Patients with inoperable non-metastatic central NSCLC (T1-T3 N0 M0, ≤7cm) were included. After prospective central imaging review and radiation therapy quality assurance for any eligible patient, SBRT (8 × 7.5 Gy) was delivered. The primary endpoint was freedom from local progression probability three years after the start of SBRT. RESULTS: The trial was closed early due to poor accrual related to repeated safety-related pauses in recruitment. Between August 2015 and December 2017, 39 patients from six European countries were included and 31 were treated per protocol and analyzed. Patients were mainly male (58%) with a median age of 75 years. Baseline comorbidities were mainly respiratory (68%) and cardiac (48%). Median tumor size was 2.6 cm (range 1.2-5.5) and most cancers were T1 (51.6%) or T2a (38.7%) N0 M0 and of squamous cell origin (48.4%). Six patients (19.4%) had an ultracentral tumor location. The median follow-up was 3.6 years. The rates of 3-year freedom from local progression and overall survival were 81.5% (90% confidence interval [CI]: 62.7%-91.4%) and 61.1% (90% CI: 44.1%-74.4%), respectively. Cumulative incidence rates of local, regional, and distant progression at three years were 6.7% (90% CI: 1.6%-17.1%), 3.3% (90% CI: 0.4%-12.4%), and 29.8% (90% CI: 16.8%-44.1%), respectively. SBRT-related acute adverse events and late adverse events ≥ G3 were reported in 6.5% (n = 2, including one G5 pneumonitis in a patient with prior interstitial lung disease) and 19.4% (n = 6, including one lethal hemoptysis after a lung biopsy in a patient receiving anticoagulants), respectively. CONCLUSIONS: The LungTech trial suggests that SBRT with 8 × 7.5Gy for central lung tumors in inoperable patients is associated with acceptable local control rates. However, late severe adverse events may occur after completion of treatment. This SBRT regimen is a viable treatment option after a thorough risk-benefit discussion with patients. To minimize potentially fatal toxicity, careful management of dose constraints, and post-SBRT interventions is crucial.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, Gustave Roussy, Université Paris Saclay, Villejuif, France.
- Department of Radiation Oncology, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany; German Cancer Consortium (DKTK), Partner Site Freiburg, Freiburg, Germany.
- Department of Radiation Oncology, Catharina Hospital, Eindhoven, The Netherlands.
- Department of Radiotherapy, Royal Marsden NHS Foundation Trust/Institute of Cancer Research, Sutton, United Kingdom.
- Department of Oncology and Radiotherapy, Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom.
- Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Förderung
- Cancer Research UK
- Roche
- Deutsche Krebshilfe
- Manchester Biomedical Research Centre
- National Institute for Health and Care Research
- Bundesministerium für Bildung und Forschung
- Deutschen Konsortium für Translationale Krebsforschung
- AstraZeneca
Zitieren
APA
Levy, A., Adebahr, S., Hurkmans, C., Ahmed, M., Ahmad, S., Guckenberger, M., Geets, X., Lievens, Y., Lambrecht, M., Pourel, N., Lewitzki, V., Konopa, K., Franks, K., Dziadziuszko, R., McDonald, F., Fortpied, C., Clementel, E., Fournier, B., Rizzo, S., …, & Nestle, U. (2024). Stereotactic Body Radiotherapy for Centrally Located Inoperable Early-Stage NSCLC: EORTC 22113–08113 LungTech Phase II Trial Results. Journal of Thoracic Oncology, 19(9), 1297-1309. https://doi.org/10.1016/j.jtho.2024.05.366
Vancouver
Levy A, Adebahr S, Hurkmans C, Ahmed M, Ahmad S, Guckenberger M, et al. Stereotactic Body Radiotherapy for Centrally Located Inoperable Early-Stage NSCLC: EORTC 22113–08113 LungTech Phase II Trial Results. Journal of Thoracic Oncology. 2024;19(9):1297-1309. doi:10.1016/j.jtho.2024.05.366
BibTeX
@article{Levy2024,
author = {Levy, Antonin and Adebahr, Sonja and Hurkmans, Coen and Ahmed, Merina and Ahmad, Shahreen and Guckenberger, Matthias and Geets, Xavier and Lievens, Yolande and Lambrecht, Maarten and Pourel, Nicolas and Lewitzki, Victor and Konopa, Krzysztof and Franks, Kevin and Dziadziuszko, Rafal and McDonald, Fiona and Fortpied, Catherine and Clementel, Enrico and Fournier, Béatrice and Rizzo, Stefania and Fink, Christian and Riesterer, Oliver and Peulen, Heike and Andratschke, Nicolaus and McWilliam, Alan and Gkika, Eleni and Schimek-Jasch, Tanja and Grosu, Anca-Ligia and Le Pechoux, Cécile and Faivre-Finn, Corinne and Nestle, Ursula},
title = {Stereotactic Body Radiotherapy for Centrally Located Inoperable Early-Stage NSCLC: EORTC 22113–08113 LungTech Phase II Trial Results},
journal = {Journal of Thoracic Oncology},
year = {2024},
volume = {19},
number = {9},
pages = {1297--1309},
doi = {10.1016/j.jtho.2024.05.366}
}
EUVIMED